Eligibility
Who May Be Eligible for Tirzepatide?
Eligibility for tirzepatide is a clinical judgement, not a checklist a website can complete. Approved labelling defines BMI thresholds for weight management and a diabetes indication for Mounjaro, but a prescriber also weighs contraindications, other medications, pregnancy plans, and comorbidities. A personal or family history of medullary thyroid carcinoma or MEN2 is a labelled contraindication.
Key takeaways
- Approved labelling sets BMI-based criteria for weight management and a separate diabetes indication.
- Medullary thyroid carcinoma history and MEN2 are labelled contraindications.
- Pregnancy, planned pregnancy, and breastfeeding require specific discussion with a prescriber.
- Concurrent insulin or sulfonylurea use changes the risk picture and may require adjustment.
- No website can determine your eligibility — this page describes the framework, not a decision.
| Weight-management criteria | BMI thresholds with or without a weight-related comorbidity, per labelling |
|---|---|
| Diabetes indication | Type 2 diabetes (Mounjaro) |
| Labelled contraindications | Personal or family history of medullary thyroid carcinoma; MEN2 |
| Pregnancy | Requires specific prescriber discussion |
| Assessment | Clinical judgement, not self-assessment |
What does approved labelling actually require?
For chronic weight management, labelling defines BMI thresholds, with a lower threshold when a weight-related comorbidity such as hypertension, dyslipidaemia, or obstructive sleep apnoea is present. For type 2 diabetes, the indication is glycaemic control. Meeting a threshold makes someone potentially eligible; it does not make treatment appropriate.
What would make tirzepatide inappropriate?
Labelled contraindications include a personal or family history of medullary thyroid carcinoma and multiple endocrine neoplasia syndrome type 2. Prior serious hypersensitivity to tirzepatide is another. Beyond contraindications, a prescriber weighs pancreatitis history, gallbladder disease, severe gastrointestinal disease, pregnancy plans, and interacting medications.
Why can a telehealth intake form not settle this?
Because a form captures what a patient reports, and the relevant history is often not something a patient knows to report — a relative's thyroid cancer, for example. A short questionnaire with no clinician conversation is a meaningful quality signal about a provider, which is why intake quality appears in this site's provider reviews.
What the evidence shows
- Approved labelling defines eligibility criteria and contraindications.
- Clinical assessment considers factors beyond BMI.
What the evidence does not show
- That meeting a BMI threshold means treatment is appropriate for you.
- That an online form substitutes for clinical assessment.
Related: Contraindications · Pregnancy
How large is the effect across the verified trials?
| Trial arm | Point estimate | Range | N |
|---|---|---|---|
| SURMOUNT-1 · 15 mg | 20.9% | 19.5% to 22.3% | 2,539 |
| SURMOUNT-1 · 10 mg | 19.5% | 18.2% to 20.8% | 2,539 |
| SURMOUNT-1 · 5 mg | 15.0% | 13.8% to 16.2% | 2,539 |
| SURMOUNT-2 · 15 mg | 14.7% | 13.4% to 16.0% | 938 |
| SURMOUNT-2 · 10 mg | 12.8% | 11.5% to 14.1% | 938 |
| SURMOUNT-1 · placebo | 3.1% | 2.3% to 3.9% | 2,539 |
When was each piece of this evidence established?
| Date | Event |
|---|---|
| May 2022 | Tirzepatide approved as Mounjaro for type 2 diabetes |
| Jun 2022 | SURMOUNT-1 published in the New England Journal of Medicine |
| Jul 2023 | SURMOUNT-2 published in the Lancet |
| Nov 2023 | Tirzepatide approved as Zepbound for chronic weight management |
| Dec 2023 | SURMOUNT-4 withdrawal results published in JAMA |
| Jun 2024 | SURMOUNT-OSA published; obstructive sleep apnoea evidence established |
| May 2025 | SURMOUNT-5 head-to-head against semaglutide published in NEJM |
What does a rigorous intake actually look like?
It asks about thyroid cancer in you and your family by name rather than as a general 'any cancer history' question, because people do not classify a relative's thyroid cancer as their own history. It asks about MEN2 specifically. It asks about prior pancreatitis, gallbladder disease, and gastroparesis. It captures a complete medication list including insulin and sulfonylureas. It asks about pregnancy status, pregnancy plans, and contraception method.
An intake that reduces to a BMI figure and a checkbox has not performed an assessment; it has collected a justification. The difference matters most for exactly the people the contraindications exist to protect.
Where does clinical discretion legitimately operate?
Between the labelled criteria and the individual. Labelling defines thresholds; it does not decide whether treatment is appropriate for a specific person with a specific history, comorbidity profile, and set of alternatives already tried. A prescriber may reasonably decline for someone who meets the criteria, or prescribe off-label for someone who does not, and both decisions are within normal practice.
What is not clinical discretion is a platform whose incentive is enrolment applying the loosest defensible reading to everyone. That is a business model, and the distinction is visible in whether anyone is ever told no.
What does this page cover, and what does it deliberately leave out?
This page addresses Indications, BMI, comorbidities and contraindications and discretion, organised around the primary question of tirzepatide eligibility. Each of those elements is treated separately below rather than blended, because they carry different evidence weights and a reader is entitled to know which parts rest on randomised data and which rest on a captured commercial claim or a regulatory document.
| Element | Treatment here | Evidence basis |
|---|---|---|
| Indications | Covered on this page | Primary evidence |
| Bmi | Covered on this page | Primary evidence |
| Comorbidities | Covered on this page | Primary evidence |
| Contraindications and discretion | Covered on this page | Primary evidence |
| Individualized clinical instruction | Deliberately not covered | Belongs with a prescriber who knows your history |
What are the limits of what this page can tell you?
Every page on this site rests on a specific clinical evidence, and that record has boundaries worth stating plainly rather than leaving a reader to discover them. The limitations below are specific to the material presented above.
- The evidence here describes groups, populations, or captured records — it does not describe you, and no page can substitute for a prescriber who knows your history.
- Figures carry the date on which they were verified. In a market where terms change frequently, an undated figure functions as a claim about the present that nobody has checked.
- Elements marked Verification Pending are genuinely unknown to this publication rather than merely omitted for brevity, and should not be inferred from surrounding content.
- Where a source conflicts with another, this site shows the conflict rather than resolving it, which means some questions are left open on purpose.
What would change the conclusion on this page?
This conclusion is held open to the following evidence:
- New primary evidence bearing directly on tirzepatide eligibility.
- A change to FDA labelling affecting any statement made above.
- A verified correction submitted through the corrections process and accepted on the evidence.
- A material change to a captured record, including a price, term, or regulatory status.
- Completion of a verification currently marked pending, which would replace a gap with a stated fact.
What do the technical terms on this page mean?
Definitions for the 7 technical terms this page uses, including MEN2, contraindication, medullary thyroid carcinoma, off-label — in the specific sense used above.
| MEN2 | Multiple endocrine neoplasia syndrome type 2. An inherited condition that predisposes to medullary thyroid carcinoma, and a labelled contraindication to tirzepatide. |
|---|---|
| contraindication | A circumstance in which a drug should not be used at all. For tirzepatide these include a personal or family history of medullary thyroid carcinoma and MEN2. |
| medullary thyroid carcinoma | A form of thyroid cancer with a strong hereditary component. A personal or family history of it is a labelled contraindication to tirzepatide. |
| off-label | Use of an approved drug for an indication, population, or dose not covered by its approved labelling. It is legal for a prescriber but means the specific use was not reviewed by the FDA. |
| pancreatitis | Inflammation of the pancreas. It appears in tirzepatide labelling as a serious potential adverse event, and presents characteristically as severe upper abdominal pain radiating to the back. |
| placebo | An inactive comparator given so that the effect of the drug can be separated from the effect of being in a trial. Placebo groups in the SURMOUNT trials still lost some weight, which is why the placebo-subtracted difference matters more than the raw figure. |
| sulfonylurea | A class of oral diabetes medication that stimulates insulin release regardless of glucose level, which is why combining it with tirzepatide raises hypoglycaemia risk. |
Frequently asked questions
Am I eligible for tirzepatide?
That requires a prescriber's assessment. This page describes the labelled framework, not a personal determination.
What are the contraindications?
Labelled contraindications include personal or family history of medullary thyroid carcinoma, MEN2, and prior serious hypersensitivity.
Can I take it if I'm trying to conceive?
Pregnancy and planned pregnancy require specific discussion with a prescriber before starting.
Do I need a certain BMI?
Labelling sets BMI thresholds for weight management, with a lower threshold when a weight-related comorbidity is present.
Change history
| Date | Change |
|---|---|
| 2026-07-22 | Page published with current dataset snapshot. |
Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.